Related Experiment Videos
Floxuridine-associated sclerosing cholangitis. A dog model
J C Andrews1, J Knol, I Wollner
1Department of Radiology, University of Michigan Medical School, Ann Arbor.
Investigative Radiology
|January 1, 1989
Summary
Researchers created a canine model to study biliary sclerosis, a complication of hepatic arterial floxuridine (FUDR) infusions for liver cancer. This model accurately replicates human patient toxicity, aiding in understanding and managing this severe side effect.
Area of Science:
- Hepatobiliary Medicine
- Oncology Drug Delivery
- Comparative Pathology
Background:
- Hepatic arterial floxuridine (FUDR) infusions are used for liver cancer but can cause severe biliary sclerosis.
- A reliable animal model is needed to study this complication and its mechanisms.
Purpose of the Study:
- To develop and validate a canine model for studying biliary sclerosis induced by FUDR infusion.
- To compare the toxic effects of FUDR in dogs to observed toxicity in human patients.
Main Methods:
- Ten mixed-breed dogs underwent surgery for gallbladder removal and cystic duct catheterization connected to infusion ports.
- Five dogs received daily FUDR infusions (0.3 mg/kg) for 30 days via implanted pumps; five control dogs received saline.
- Cholangiography and liver function tests were performed before and after treatment.
Main Results:
- FUDR-treated dogs showed elevated liver enzymes (AST, ALP) and hyperbilirubinemia.
- Cholangiography revealed biliary strictures in the central bile ducts and diffuse intrahepatic duct attenuation in treated dogs.
- Control dogs exhibited normal liver function and biliary tree appearance.
Conclusions:
- The developed canine model successfully replicates the hepatobiliary toxicity observed in human patients receiving hepatic arterial FUDR infusions.
- This model provides a valuable tool for investigating the pathogenesis of FUDR-induced biliary sclerosis and for testing potential therapeutic interventions.